世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

AAVベクター遺伝子治療の世界市場成長 2023-2029


Global AAV Vector Gene Therapy Market Growth 2023-2029

LPI(エルピーアイ情報)の最新調査によると、AAVベクター遺伝子治療の世界市場規模は2022年に100万米ドルと評価されました。下流市場での需要の増加に伴い、AAVベクター遺伝子治療は2029年までに100万米ドルの再... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年11月7日 US$3,660
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
96 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(エルピーアイ情報)の最新調査によると、AAVベクター遺伝子治療の世界市場規模は2022年に100万米ドルと評価されました。下流市場での需要の増加に伴い、AAVベクター遺伝子治療は2029年までに100万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは%である。
この調査レポートは、世界のAAVベクター遺伝子治療市場の成長可能性を明らかにしています。AAVベクター遺伝子治療は、今後の市場でも安定した成長が期待されます。しかし、AAVベクター遺伝子治療の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要です。市場関係者は、AAVベクター遺伝子治療市場がもたらす莫大な機会を活用するために、研究開発への投資、戦略的パートナーシップの構築、進化する消費者の嗜好に合わせた製品提供を行う必要がある。
AAV(アデノ随伴ウイルス)ベクター遺伝子治療は、アデノ随伴ウイルスをベクターとして使用し、患者に特定の遺伝子を導入、発現、修復させる遺伝子治療法である。AAVは非病原性、非発癌性ウイルスであり、遺伝子治療研究や臨床試験で広く使用されている。
主な特徴
AAVベクター遺伝子治療市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、AAVベクター遺伝子治療市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(AAV1、AAV2など)、地域別内訳を含む場合があります。
市場促進要因と課題:政府規制、環境問題、技術進歩、消費者の嗜好の変化など、AAVベクター遺伝子治療市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、初期コストの高さなど、業界が直面する課題も明らかにすることができます。
競合情勢:この調査レポートは、AAVベクター遺伝子治療市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興企業やその市場に与える潜在的な影響にもスポットを当てています。
技術開発:調査レポートは、AAVベクター遺伝子治療業界における最新の技術開発を掘り下げることができます。これには、AAV Vector Gene Therapy技術の進歩、AAV Vector Gene Therapyの新規参入、AAV Vector Gene Therapyの新規投資、AAV Vector Gene Therapyの将来を形作るその他の技術革新などが含まれます。
川下企業の好み:この調査レポートは、AAVベクター遺伝子治療市場における顧客の購買行動や採用動向を明らかにします。顧客の購買決定やAAVベクター遺伝子治療製品の嗜好に影響を与える要因も含まれています。
政府の政策とインセンティブこの調査レポートは、政府の政策とインセンティブがAAVベクター遺伝子治療市場に与える影響を分析しています。これには、AAVベクター遺伝子治療市場の促進を目的とした規制の枠組み、補助金、税制優遇措置などの評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価します。
環境への影響と持続可能性この調査レポートは、AAVベクター遺伝子治療市場の環境への影響と持続可能性の側面を評価します。
市場予測と将来展望:調査レポートでは、実施した分析に基づいて、AAVベクター遺伝子治療産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、AAVベクター遺伝子治療市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
AAVベクター遺伝子治療市場は、タイプ別と用途別に分類されます。2018年から2029年までの期間について、セグメント間の成長により、タイプ別、アプリケーション別の消費額の正確な計算と予測を数量と金額で提供します。
タイプ別セグメント
AAV1
AAV2
AAV8
その他
用途別セグメント
デュシェンヌ型ジストロフィー
血友病
網膜疾患
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ユニキュア
ロシュ
ノバルティス
バイオマリン製薬
フェリング・ファーマシューティカルズA/S
CSLベーリングLLC
PTCセラピューティクス社
ファイザー
本レポートで扱う主な質問
世界のAAVベクター遺伝子治療市場の10年間の見通しは?
AAVベクター遺伝子治療の世界市場および地域別市場成長の要因は何か?
市場別・地域別で最も急成長する技術は何か?
AAVベクター遺伝子治療の市場機会は最終市場規模によってどのように異なるのか?
AAVベクター遺伝子治療のタイプ別、用途別内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global AAV Vector Gene Therapy Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for AAV Vector Gene Therapy by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for AAV Vector Gene Therapy by Country/Region, 2018, 2022 & 2029
2.2 AAV Vector Gene Therapy Segment by Type
2.2.1 AAV1
2.2.2 AAV2
2.2.3 AAV8
2.2.4 Other
2.3 AAV Vector Gene Therapy Sales by Type
2.3.1 Global AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)
2.3.2 Global AAV Vector Gene Therapy Revenue and Market Share by Type (2018-2023)
2.3.3 Global AAV Vector Gene Therapy Sale Price by Type (2018-2023)
2.4 AAV Vector Gene Therapy Segment by Application
2.4.1 Duchenne Dystrophy
2.4.2 Hemophilia
2.4.3 Retinal Diseases
2.4.4 Other
2.5 AAV Vector Gene Therapy Sales by Application
2.5.1 Global AAV Vector Gene Therapy Sale Market Share by Application (2018-2023)
2.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Application (2018-2023)
2.5.3 Global AAV Vector Gene Therapy Sale Price by Application (2018-2023)
3 Global AAV Vector Gene Therapy by Company
3.1 Global AAV Vector Gene Therapy Breakdown Data by Company
3.1.1 Global AAV Vector Gene Therapy Annual Sales by Company (2018-2023)
3.1.2 Global AAV Vector Gene Therapy Sales Market Share by Company (2018-2023)
3.2 Global AAV Vector Gene Therapy Annual Revenue by Company (2018-2023)
3.2.1 Global AAV Vector Gene Therapy Revenue by Company (2018-2023)
3.2.2 Global AAV Vector Gene Therapy Revenue Market Share by Company (2018-2023)
3.3 Global AAV Vector Gene Therapy Sale Price by Company
3.4 Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers AAV Vector Gene Therapy Product Location Distribution
3.4.2 Players AAV Vector Gene Therapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for AAV Vector Gene Therapy by Geographic Region
4.1 World Historic AAV Vector Gene Therapy Market Size by Geographic Region (2018-2023)
4.1.1 Global AAV Vector Gene Therapy Annual Sales by Geographic Region (2018-2023)
4.1.2 Global AAV Vector Gene Therapy Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic AAV Vector Gene Therapy Market Size by Country/Region (2018-2023)
4.2.1 Global AAV Vector Gene Therapy Annual Sales by Country/Region (2018-2023)
4.2.2 Global AAV Vector Gene Therapy Annual Revenue by Country/Region (2018-2023)
4.3 Americas AAV Vector Gene Therapy Sales Growth
4.4 APAC AAV Vector Gene Therapy Sales Growth
4.5 Europe AAV Vector Gene Therapy Sales Growth
4.6 Middle East & Africa AAV Vector Gene Therapy Sales Growth
5 Americas
5.1 Americas AAV Vector Gene Therapy Sales by Country
5.1.1 Americas AAV Vector Gene Therapy Sales by Country (2018-2023)
5.1.2 Americas AAV Vector Gene Therapy Revenue by Country (2018-2023)
5.2 Americas AAV Vector Gene Therapy Sales by Type
5.3 Americas AAV Vector Gene Therapy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AAV Vector Gene Therapy Sales by Region
6.1.1 APAC AAV Vector Gene Therapy Sales by Region (2018-2023)
6.1.2 APAC AAV Vector Gene Therapy Revenue by Region (2018-2023)
6.2 APAC AAV Vector Gene Therapy Sales by Type
6.3 APAC AAV Vector Gene Therapy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe AAV Vector Gene Therapy by Country
7.1.1 Europe AAV Vector Gene Therapy Sales by Country (2018-2023)
7.1.2 Europe AAV Vector Gene Therapy Revenue by Country (2018-2023)
7.2 Europe AAV Vector Gene Therapy Sales by Type
7.3 Europe AAV Vector Gene Therapy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa AAV Vector Gene Therapy by Country
8.1.1 Middle East & Africa AAV Vector Gene Therapy Sales by Country (2018-2023)
8.1.2 Middle East & Africa AAV Vector Gene Therapy Revenue by Country (2018-2023)
8.2 Middle East & Africa AAV Vector Gene Therapy Sales by Type
8.3 Middle East & Africa AAV Vector Gene Therapy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy
10.3 Manufacturing Process Analysis of AAV Vector Gene Therapy
10.4 Industry Chain Structure of AAV Vector Gene Therapy
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 AAV Vector Gene Therapy Distributors
11.3 AAV Vector Gene Therapy Customer
12 World Forecast Review for AAV Vector Gene Therapy by Geographic Region
12.1 Global AAV Vector Gene Therapy Market Size Forecast by Region
12.1.1 Global AAV Vector Gene Therapy Forecast by Region (2024-2029)
12.1.2 Global AAV Vector Gene Therapy Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global AAV Vector Gene Therapy Forecast by Type
12.7 Global AAV Vector Gene Therapy Forecast by Application
13 Key Players Analysis
13.1 uniQure
13.1.1 uniQure Company Information
13.1.2 uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
13.1.3 uniQure AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 uniQure Main Business Overview
13.1.5 uniQure Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche AAV Vector Gene Therapy Product Portfolios and Specifications
13.2.3 Roche AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
13.3.3 Novartis AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 BioMarin Pharmaceutical
13.4.1 BioMarin Pharmaceutical Company Information
13.4.2 BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications
13.4.3 BioMarin Pharmaceutical AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 BioMarin Pharmaceutical Main Business Overview
13.4.5 BioMarin Pharmaceutical Latest Developments
13.5 Ferring Pharmaceuticals A/S
13.5.1 Ferring Pharmaceuticals A/S Company Information
13.5.2 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications
13.5.3 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ferring Pharmaceuticals A/S Main Business Overview
13.5.5 Ferring Pharmaceuticals A/S Latest Developments
13.6 CSL Behring LLC
13.6.1 CSL Behring LLC Company Information
13.6.2 CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications
13.6.3 CSL Behring LLC AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Behring LLC Main Business Overview
13.6.5 CSL Behring LLC Latest Developments
13.7 PTC Therapeutics, Inc.
13.7.1 PTC Therapeutics, Inc. Company Information
13.7.2 PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.7.3 PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 PTC Therapeutics, Inc. Main Business Overview
13.7.5 PTC Therapeutics, Inc. Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.8.3 Pfizer Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global AAV Vector Gene Therapy market size was valued at US$ million in 2022. With growing demand in downstream market, the AAV Vector Gene Therapy is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global AAV Vector Gene Therapy market. AAV Vector Gene Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of AAV Vector Gene Therapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the AAV Vector Gene Therapy market.
AAV (Adeno-Associated Virus) vector gene therapy is a gene therapy method that uses adeno-associated virus as a vector to deliver, express or repair specific genes in patients. AAV is a non-pathogenic, non-oncogenic virus that is widely used in gene therapy research and clinical trials.
Key Features:
The report on AAV Vector Gene Therapy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the AAV Vector Gene Therapy market. It may include historical data, market segmentation by Type (e.g., AAV1, AAV2), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the AAV Vector Gene Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the AAV Vector Gene Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the AAV Vector Gene Therapy industry. This include advancements in AAV Vector Gene Therapy technology, AAV Vector Gene Therapy new entrants, AAV Vector Gene Therapy new investment, and other innovations that are shaping the future of AAV Vector Gene Therapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the AAV Vector Gene Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for AAV Vector Gene Therapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the AAV Vector Gene Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting AAV Vector Gene Therapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the AAV Vector Gene Therapy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the AAV Vector Gene Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the AAV Vector Gene Therapy market.
Market Segmentation:
AAV Vector Gene Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
AAV1
AAV2
AAV8
Other
Segmentation by application
Duchenne Dystrophy
Hemophilia
Retinal Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
uniQure
Roche
Novartis
BioMarin Pharmaceutical
Ferring Pharmaceuticals A/S
CSL Behring LLC
PTC Therapeutics, Inc.
Pfizer Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global AAV Vector Gene Therapy market?
What factors are driving AAV Vector Gene Therapy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do AAV Vector Gene Therapy market opportunities vary by end market size?
How does AAV Vector Gene Therapy break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global AAV Vector Gene Therapy Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for AAV Vector Gene Therapy by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for AAV Vector Gene Therapy by Country/Region, 2018, 2022 & 2029
2.2 AAV Vector Gene Therapy Segment by Type
2.2.1 AAV1
2.2.2 AAV2
2.2.3 AAV8
2.2.4 Other
2.3 AAV Vector Gene Therapy Sales by Type
2.3.1 Global AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)
2.3.2 Global AAV Vector Gene Therapy Revenue and Market Share by Type (2018-2023)
2.3.3 Global AAV Vector Gene Therapy Sale Price by Type (2018-2023)
2.4 AAV Vector Gene Therapy Segment by Application
2.4.1 Duchenne Dystrophy
2.4.2 Hemophilia
2.4.3 Retinal Diseases
2.4.4 Other
2.5 AAV Vector Gene Therapy Sales by Application
2.5.1 Global AAV Vector Gene Therapy Sale Market Share by Application (2018-2023)
2.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Application (2018-2023)
2.5.3 Global AAV Vector Gene Therapy Sale Price by Application (2018-2023)
3 Global AAV Vector Gene Therapy by Company
3.1 Global AAV Vector Gene Therapy Breakdown Data by Company
3.1.1 Global AAV Vector Gene Therapy Annual Sales by Company (2018-2023)
3.1.2 Global AAV Vector Gene Therapy Sales Market Share by Company (2018-2023)
3.2 Global AAV Vector Gene Therapy Annual Revenue by Company (2018-2023)
3.2.1 Global AAV Vector Gene Therapy Revenue by Company (2018-2023)
3.2.2 Global AAV Vector Gene Therapy Revenue Market Share by Company (2018-2023)
3.3 Global AAV Vector Gene Therapy Sale Price by Company
3.4 Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers AAV Vector Gene Therapy Product Location Distribution
3.4.2 Players AAV Vector Gene Therapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for AAV Vector Gene Therapy by Geographic Region
4.1 World Historic AAV Vector Gene Therapy Market Size by Geographic Region (2018-2023)
4.1.1 Global AAV Vector Gene Therapy Annual Sales by Geographic Region (2018-2023)
4.1.2 Global AAV Vector Gene Therapy Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic AAV Vector Gene Therapy Market Size by Country/Region (2018-2023)
4.2.1 Global AAV Vector Gene Therapy Annual Sales by Country/Region (2018-2023)
4.2.2 Global AAV Vector Gene Therapy Annual Revenue by Country/Region (2018-2023)
4.3 Americas AAV Vector Gene Therapy Sales Growth
4.4 APAC AAV Vector Gene Therapy Sales Growth
4.5 Europe AAV Vector Gene Therapy Sales Growth
4.6 Middle East & Africa AAV Vector Gene Therapy Sales Growth
5 Americas
5.1 Americas AAV Vector Gene Therapy Sales by Country
5.1.1 Americas AAV Vector Gene Therapy Sales by Country (2018-2023)
5.1.2 Americas AAV Vector Gene Therapy Revenue by Country (2018-2023)
5.2 Americas AAV Vector Gene Therapy Sales by Type
5.3 Americas AAV Vector Gene Therapy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AAV Vector Gene Therapy Sales by Region
6.1.1 APAC AAV Vector Gene Therapy Sales by Region (2018-2023)
6.1.2 APAC AAV Vector Gene Therapy Revenue by Region (2018-2023)
6.2 APAC AAV Vector Gene Therapy Sales by Type
6.3 APAC AAV Vector Gene Therapy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe AAV Vector Gene Therapy by Country
7.1.1 Europe AAV Vector Gene Therapy Sales by Country (2018-2023)
7.1.2 Europe AAV Vector Gene Therapy Revenue by Country (2018-2023)
7.2 Europe AAV Vector Gene Therapy Sales by Type
7.3 Europe AAV Vector Gene Therapy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa AAV Vector Gene Therapy by Country
8.1.1 Middle East & Africa AAV Vector Gene Therapy Sales by Country (2018-2023)
8.1.2 Middle East & Africa AAV Vector Gene Therapy Revenue by Country (2018-2023)
8.2 Middle East & Africa AAV Vector Gene Therapy Sales by Type
8.3 Middle East & Africa AAV Vector Gene Therapy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy
10.3 Manufacturing Process Analysis of AAV Vector Gene Therapy
10.4 Industry Chain Structure of AAV Vector Gene Therapy
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 AAV Vector Gene Therapy Distributors
11.3 AAV Vector Gene Therapy Customer
12 World Forecast Review for AAV Vector Gene Therapy by Geographic Region
12.1 Global AAV Vector Gene Therapy Market Size Forecast by Region
12.1.1 Global AAV Vector Gene Therapy Forecast by Region (2024-2029)
12.1.2 Global AAV Vector Gene Therapy Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global AAV Vector Gene Therapy Forecast by Type
12.7 Global AAV Vector Gene Therapy Forecast by Application
13 Key Players Analysis
13.1 uniQure
13.1.1 uniQure Company Information
13.1.2 uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
13.1.3 uniQure AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 uniQure Main Business Overview
13.1.5 uniQure Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche AAV Vector Gene Therapy Product Portfolios and Specifications
13.2.3 Roche AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
13.3.3 Novartis AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 BioMarin Pharmaceutical
13.4.1 BioMarin Pharmaceutical Company Information
13.4.2 BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications
13.4.3 BioMarin Pharmaceutical AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 BioMarin Pharmaceutical Main Business Overview
13.4.5 BioMarin Pharmaceutical Latest Developments
13.5 Ferring Pharmaceuticals A/S
13.5.1 Ferring Pharmaceuticals A/S Company Information
13.5.2 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications
13.5.3 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ferring Pharmaceuticals A/S Main Business Overview
13.5.5 Ferring Pharmaceuticals A/S Latest Developments
13.6 CSL Behring LLC
13.6.1 CSL Behring LLC Company Information
13.6.2 CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications
13.6.3 CSL Behring LLC AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Behring LLC Main Business Overview
13.6.5 CSL Behring LLC Latest Developments
13.7 PTC Therapeutics, Inc.
13.7.1 PTC Therapeutics, Inc. Company Information
13.7.2 PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.7.3 PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 PTC Therapeutics, Inc. Main Business Overview
13.7.5 PTC Therapeutics, Inc. Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.8.3 Pfizer Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/06/18 10:26

158.74 円

170.83 円

204.52 円

ページTOPに戻る